News
4h
Zacks Investment Research on MSNWill Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results